Comparative Study of the Efficacy and Side Effects of Liposomal Platinum-Based Nanodrugs Versus Conventional Chemotherapy in the Treatment of Advanced Colon Cancer
Comparative Study of the Efficacy and Side Effects of Liposomal Platinum-Based Nanodrugs Versus Conventional Chemotherapy in the Treatment of Advanced Colon Cancer
Rozhaneh Babaei,1,*ABDOLREZA SABOKROUH,2
1. M.Sc. Student in Biochemistry Faculty of New Sciences and Technologies Islamic Azad University, Tehran Medical Sciences Branch Tehran, Iran 2. Department of Biochemistry,Faculty of Medicine,Tehran Medical Sciences, Islamic Azad University,Tehran,Iran
Introduction: The treatment of advanced colon cancer has historically relied on conventional chemotherapy, which, despite its efficacy, often results in significant side effects that impact patients' quality of life. In recent years, advancements in nanotechnology have introduced liposomal platinum-based nanodrugs as a promising alternative. These nanodrugs are designed to enhance the delivery of chemotherapeutic agents directly to cancer cells, potentially increasing efficacy and reducing systemic toxicity. This study aims to compare the efficacy and side effects of liposomal platinum-based nanodrugs with those of traditional chemotherapy in patients with advanced colon cancer.
Methods: This comparative study was conducted on a sample size of 200 patients diagnosed with advanced colon cancer. The sample included 120 males and 80 females, with a mean age of 55 years. The participants were randomly divided into two groups: the experimental group (Group A), which received liposomal platinum-based nanodrugs, and the control group (Group B), which received conventional chemotherapy. Each group consisted of 100 patients. The treatment regimen for Group A involved the administration of liposomal platinum-based nanodrugs at a dose determined by body surface area, while Group B received standard doses of conventional chemotherapeutic agents. The primary endpoints were overall survival (OS), progression-free survival (PFS), and incidence of side effects, which were monitored over a 12-month period. Secondary endpoints included quality of life assessments and response rates, measured through imaging and biomarker analysis.
Results: The study revealed that the overall survival rate at 12 months was significantly higher in Group A (70 patients) compared to Group B (55 patients). Progression-free survival was also notably improved in Group A, with 65 patients showing no disease progression at the end of the study period, compared to 50 patients in Group B. The incidence of severe side effects, such as grade 3 and 4 neutropenia, was lower in Group A (20 patients) compared to Group B (35 patients). Additionally, gastrointestinal toxicity, including nausea and vomiting, was reported in 30 patients in Group A and 45 patients in Group B. Quality of life assessments indicated that patients in Group A had better overall scores, with 60 patients reporting significant improvements, compared to 40 patients in Group B. Response rates, determined through imaging, showed that 50 patients in Group A had partial or complete tumor reduction, whereas only 35 patients in Group B demonstrated similar outcomes.
Conclusion: The findings of this study suggest that liposomal platinum-based nanodrugs offer a superior alternative to conventional chemotherapy in the treatment of advanced colon cancer. The enhanced efficacy, evidenced by higher overall survival and progression-free survival rates, coupled with a lower incidence of severe side effects, highlights the potential of nanodrug therapy to improve patient outcomes. These results support further research and development of liposomal nanodrugs as a viable option in oncological treatment protocols